Which GLP-1 Makes You Lose the Most Weight?

Last reviewed: June 7, 2026

Last updated: June 7, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

The question of which GLP-1 medication produces the most dramatic weight loss has a straightforward answer in large clinical trials: tirzepatide outperforms semaglutide by approximately 2-3 percentage points of body weight reduction. However, real-world results vary significantly between individuals, making personalized selection more important than chasing the highest average number.

Tirzepatide vs. Semaglutide: Direct Weight Loss Comparison

Clinical evidence demonstrates that tirzepatide achieves mean weight loss of 22% of baseline body weight at maximum doses, while semaglutide reaches approximately 18-19% at comparable therapeutic levels. This difference stems from tirzepatide's dual mechanism—it activates both GLP-1 and GIP receptors in the brain and gut, whereas semaglutide targets GLP-1 alone. Neither result represents a guaranteed outcome for any individual patient.

The SURMOUNT and SELECT trials established tirzepatide's superior weight reduction profile in large populations, but these studies included thousands of participants with varying genetics, metabolic rates, and lifestyle factors. A person with specific genetic variants affecting GIP receptor sensitivity might experience substantially better results with tirzepatide, while someone with different peptide pathway architecture could achieve equivalent outcomes with semaglutide at lower cost.

Why Individual Weight Loss Results Differ So Dramatically

Your genetic code contains over 150 variations that influence how effectively you respond to GLP-1 and GIP signaling pathways. Key variants in genes like GIPR, FTO, and MC4R directly affect appetite regulation, metabolic rate, and fat storage patterns. Two patients taking identical doses of the same medication can experience 50% differences in weight loss due to these inherited differences in peptide sensitivity.

Environmental factors including sleep quality, stress hormones, physical activity patterns, and dietary composition layer on top of genetic predisposition. A person with favorable GLP-1 receptor genetics who maintains poor sleep will experience blunted weight loss compared to someone with less optimal genetics who prioritizes recovery. This complexity explains why comparing average trial results to your personal situation is inherently misleading.

Precision Peptide Genetic Testing Reveals Your Optimal GLP-1

PlexusDx offers the Precision Peptide Genetic Test, a peptide-pathway analysis that maps your inherited variations across 14 metabolic pathways and 49 distinct peptides. This test identifies whether your biology favors single-receptor activation (semaglutide) or dual-receptor engagement (tirzepatide), helping guide medication selection based on your genetic architecture rather than population averages. The test is $298.

The PlexusDx Precision Peptide Genetic Test analyzes GIPR (rs1800437) and FTO (rs9939609) — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to tirzepatide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Starting with Semaglutide: Cost-Effective Entry to Personalized Weight Loss

Compounded semaglutide injection through PlexusDx is $189/mo month-to-month (or $149/mo on the 6-month plan), providing an accessible entry point for individuals exploring GLP-1 therapy without insurance requirements. This pricing remains flat regardless of dose escalation—your dose may need to go up, but your price won't. Many patients achieve their target weight loss with semaglutide monotherapy, eliminating the need for more expensive dual-compound protocols.

If you begin with semaglutide and after 8-12 weeks find your results plateau despite dose optimization, you can transition to tirzepatide injection (starting at $289/mo (or $249/mo on the 6-month plan)) or the GLP-Squared dual-compound option (starting at $289/mo (or $249/mo on the 3-month plan)). This staged approach allows you to discover whether you need tirzepatide's additional GIP pathway activation before committing to higher medication costs. PlexusDx serves all 50 states with medications from licensed 503A compounding pharmacies, making personalized adjustment accessible nationwide.

Oral vs. Injectable: Does Delivery Method Affect Weight Loss?

Oral semaglutide and oral tirzepatide offer convenience advantages for needle-averse patients, but injectable formulations demonstrate superior bioavailability and more predictable weight loss outcomes in comparative studies. Oral medications experience significant first-pass metabolism through the liver, reducing systemic exposure by approximately 50-60% compared to subcutaneous injection. This means oral doses require higher dosing schedules to achieve equivalent blood levels.

PlexusDx offers both delivery methods—oral semaglutide is $289/mo month-to-month (or $249/mo on the 6-month plan) and oral tirzepatide at $349/mo (or $279/mo on the 6-month plan)—allowing you to prioritize convenience if maximum weight loss represents a secondary concern. Injectable semaglutide at $189/month provides the best combination of affordability and clinical efficacy for most patients beginning personalized therapy. Your clinician can recommend the formulation matching your weight loss goals, lifestyle preferences, and genetic peptide pathway profile.

The Microdose GLP-1 Protocol: Lower Cost, Different Results Timeline

PlexusDx offers a Microdose GLP-1 Protocol at $129 per month flat, representing the most affordable entry point into GLP-1 therapy. This protocol uses lower initial doses to minimize nausea and gastrointestinal adaptation, extending the timeline to maximum weight loss over several months. Patients with sensitive metabolisms or those prioritizing cost over speed often experience excellent cumulative results with this approach.

Microdose protocols typically produce 15-18% body weight reduction over 6-9 months, similar to standard semaglutide doses over longer timeframes. This option suits individuals with modest weight loss goals (under 30 pounds), those sensitive to medication side effects, or patients using GLP-1 therapy primarily for metabolic health rather than dramatic transformation. All PlexusDx medications are HSA/FSA eligible, making the microdose protocol particularly cost-effective for eligible patients.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Will tirzepatide make me lose more weight than semaglutide?

Clinical trials show tirzepatide averages 2-3% more body weight reduction than semaglutide, but your individual response depends on your genetic peptide pathway variants. The Precision Peptide Genetic Test identifies whether your biology favors tirzepatide's dual GIP-GLP-1 mechanism or responds optimally to semaglutide monotherapy. Some patients achieve identical results with either medication due to their specific genetic architecture.

How quickly will I see weight loss results with GLP-1?

Most patients notice appetite suppression within 3-7 days of starting GLP-1 therapy, with measurable weight loss appearing within 2-4 weeks. Maximum effects require 4-6 months of dose optimization as your body reaches therapeutic steady-state. The Microdose GLP-1 Protocol extends this timeline to 6-9 months but minimizes side effects for sensitive patients.

Can I switch from semaglutide to tirzepatide if I'm not losing enough weight?

Yes, PlexusDx allows medication adjustments after 8-12 weeks if your weight loss results plateau. Semaglutide injection is $189/mo month-to-month (or $149/mo on the 6-month plan) while tirzepatide injection is $289/mo month-to-month, or from $249/mo on the 6-month plan, both with flat monthly pricing regardless of dose. Your clinician can recommend switching based on your genetic test results and response patterns.

Are compounded GLP-1 medications from PlexusDx as effective as brand-name drugs?

PlexusDx compounds all medications through licensed 503A compounding pharmacies using identical active pharmaceutical ingredients as brand-name products. Compounded and brand-name formulations have equivalent therapeutic effects when prepared to pharmaceutical standards. Cost savings come from eliminating brand markup, not from reduced medication quality.

What does the Precision Peptide Genetic Test tell me about my weight loss potential?

No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Does PlexusDx require insurance or membership fees?

PlexusDx serves all 50 states without requiring insurance or membership fees. All medications are HSA/FSA eligible, and pricing remains flat across commitment tiers—semaglutide injection is $189/mo month-to-month (or $149/mo on the 6-month plan) regardless of dose level.

Related Reading

• Glp 1 For Losing Weight
• Glp 1 For Weight Loss 2
• Glp 1 Weight Loss Before And After
• Glp 1 Dosage For Weight Loss

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.